Please assess the completion status of the following clinical trial:

Trial Title: Brexpiprazole (OPC-34712) as an Adjunctive Treatment in Adults With Major Depressive Disorder and Anxiety Symptoms

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Main Inclusion Criteria:~* Have a diagnosis of a single or recurrent, nonpsychotic episode of MDD as defined by the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR) and confirmed by both the Mini International Neuropsychiatric Interview (M.I.N.I.) and an adequate clinical psychiatric evaluation.~* Have a treatment history of an inadequate ADT response to at least 1 ADT (but not \> 3) for the current episode.~* Have received a single, trial-approved, SSRI or SNRI at an adequate dose for~  ≥ 6 weeks prior to screening.~* Are 18 to 65 years old at the time of consent (inclusive, and outpatients only).~* Have a Hamilton Depression Rating Scale (HAM-D)-17-item Total Score ≥ 18 at screening and baseline.~* Have a Hamilton Anxiety Rating Scale (HAM-A) Total Score ≥ 20 at screening and baseline.~Main Exclusion Criteria:~Subjects with any of the following current Axis I DSM-IV-TR diagnoses:~* delirium~* dementia~* amnestic~* other cognitive disorders~* schizophrenia~* schizoaffective disorder~* other psychotic disorders~* bipolar I disorder,~* bipolar II disorder~* bipolar disorder not otherwise specified (NOS)~* eating disorders~* anorexia nervosa~* bulimia~* obsessive compulsive disorder~* post-traumatic stress disorder~Subjects with any of the following current Axis II DSM-IV-TR diagnoses:~* borderline, antisocial~* paranoid~* schizoid~* schizotypal~* histrionic personality disorders~* mental retardation.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Brexpiprazole (Type: EXPERIMENTAL): Up to 3 mg/day, once daily dose, tablets, orally

Based on this trial design, predict the completion outcome and termination type (if applicable).